Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Nivolumab in Bone Metastatic Clear Cell Renal Cell Carcinoma
NCT07187869Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabozantinib in clear cell renal cell carcinoma (ccRCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year, Success rate of obtaining serial biopsies of bone metastases at 8 weeks and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07187869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187869.